Coronary/Structural Heart

Neovasc Provides Tiara TA Update

VANCOUVER and MINNEAPOLIS, April 16, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), today announced that the Tiara Transapical system (“Tiara TA”) will be unable to receive a European CE mark under the current Medical Device Directive regulations (“MDD”) ending on May 26, 2021. The Company is […]

Seigla® Medical Receives CE Mark for LiquID™ Guide Catheter Extension

MINNEAPOLIS, April 16, 2021 /PRNewswire/ — Seigla Medical, Inc., announced conformité européenne (CE) Mark for the company’s LiquID™ Guide Catheter Extension for use in coronary and peripheral vasculature interventions. Guide catheter extensions are a crucial tool used by cardiologists worldwide to assist in the delivery of stents and other interventional devices. In addition, […]

Cardionomic Announces First Patients Enrolled in CPNS Pilot Study

Study evaluates safety and performance of endovascular pulmonary neuromodulation in ADHF MINNEAPOLIS, April 15, 2021 /PRNewswire/ — Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce initial enrollment in their Cardionomic Pulmonary Neuromodulation System (CPNS) Pilot Study. The study will evaluate the safety and performance of the CPNS in patients suffering from Acute […]

Silence Therapeutics Announces Publication in Cardiovascular Research Highlighting the Emerging Potential of RNA Therapeutics in Preventing Lipoprotein(a)-Mediated Cardiovascular Disease

Silence Therapeutics Announces Publication in Cardiovascular Research Highlighting the Emerging Potential of RNA Therapeutics in Preventing Lipoprotein(a)-Mediated Cardiovascular Disease       –High Lipoprotein(a) is a genetically determined cardiovascular risk factor affecting around 20% of the world’s population  15 April 2021 LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN (“Silence” or “the Company”), […]

First Patient Enrolled in PROTECT IV Randomized Controlled Trial of Impella

DANVERS, Mass.–(BUSINESS WIRE)–Abiomed (NASDAQ:ABMD) announced today that the first patient has been enrolled in PROTECT IV, a large, prospective, multi-center randomized controlled trial (RCT) that is designed to provide the level of clinical evidence needed to achieve a Class I guideline recommendation for Impella in high-risk percutaneous coronary intervention (HRPCI). The first patient […]

NeoProgen, Inc. Receives First Granted Patent for Method to Treat Cardiac Conditions using Neonatal Heart-derived Medicinal Signaling Cells (nMSCs) and/or their Secretomes/Exosomes from the US Patent Office

BALTIMORE–(BUSINESS WIRE)–NeoProgen, Inc., a pre-clinical stage company developing an exosome-based product from human neonatal heart-derived Medicinal Signaling Cells (nMSCs) for tissue repair and regeneration for the treatment of heart failure (HF) and other inflammatory diseases, announced that it has received a patent from the United States Patent Office Patent No.: […]

Datos Health Announces New Partnership For Study Measuring Impact Of Digital Solutions On Heart Failure Treatment

Breakthrough Multicentered Study will Evaluate Efficacy of Digital Health Data Collection Outside the Clinic for Guideline-Directed Heart Failure Therapy NEW YORK, April 13, 2021 /PRNewswire/ — Datos Health, a leader in remote care automation, today announced its collaboration with Amgen, one of the world’s leading independent biotechnology companies, on a new study to evaluate […]

Valbiotis Reveals Positive TOTUM•854 Preclinical Results in the Prevention of Hypertension at the Annual ESH-ISH Joint Meeting

An acceleration of development in order to advance the marketing horizon up to 3 years, to conquer an addressable market of over one billion euros Valbiotis presents preclinical data on the plant-derived active substance TOTUM•854, designed to reduce blood pressure, at the Annual Joint Meeting of the European Society of […]

Alnylam Presents Positive Late-Breaking Data from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension

– Single Doses of Investigational ALN-AGT Achieved Sustained Reductions in Serum Angiotensinogen (AGT) at 12 Weeks Resulting in Reduced Blood Pressure – – Durability of AGT Knockdown Supports the Potential of Once Quarterly or Biannual Dosing – – ALN-AGT was Generally Well Tolerated, with No Serious Treatment-Related Adverse Events or […]

Abbott Receives CE Mark Approval for Next-Generation TriClip™ Device, Offering New Innovations for Tricuspid Heart Valve Repair

– New enhancements to first-of-its-kind device uniquely developed for the difficult-to-treat tricuspid valve – Next-generation therapy offers enhanced leaflet grasping feature and new clip sizes to fit each patient’s complex tricuspid valve anatomy – TriClip G4 makes treatment more customizable, expanding options for physicians seeking innovative transcatheter structural heart solutions […]